SECTION A: CORE QUESTIONS

A1. What are the functions/activities of this facility? Please ✓ all that apply.

☐ General Medical/Surgical Hospital
☐ Home Health Care
☐ Medical/Diagnostic Lab
☐ Nursing Care Facility
☐ Other Health Practitioners
☐ Outpatient Care Center
☐ Physician's Office
☐ Psychiatric/Substance Abuse Hospital
☐ Specialty(ies) Hospital
☐ Dentist's Office
☐ Other (Please specify): __________________

A2. Which of the following characterizes this facility? Please ✓ all that apply.

☐ For profit (individual, partnership, or corporation)
☐ Private non-profit (e.g., religious group, charity, etc.) or not-for-profit corporation
☐ City, county, district, or state government (including public university-based)
☐ Federal government (e.g., military or VHA)
☐ Other (Please specify): __________________

A3. Is this facility currently part of a managed care or health maintenance organization (HMO)?

☐ Yes
☐ No

A4. Is this facility currently accredited by the Joint Commission (JCAHO)?

☐ Yes
☐ No
☐ Not applicable
A5. What is the average daily inpatient census over the past calendar year?

Average Inpatient Census [ ]

☐ NA, This facility does not provide inpatient services

A6. What is the average number of daily outpatient appointments at this facility over the past calendar year?

[ ] 1-50
[ ] 51-100
[ ] 101-200
[ ] 201-500
[ ] 501-1000
[ ] 1001-5000
[ ] More than 5000
[ ] This facility does not provide outpatient services

A7. How many full-time equivalent (FTE) employees are currently on your payroll?

[ ] Less than 10
[ ] 10-50
[ ] 51-250
[ ] 251-1000
[ ] 1001-5000
[ ] More than 5000

A8. How many workers who provide services at this facility are not on your payroll? (Please include physicians, nurses, maintenance, housekeeping, laundry and food service.)

[ ] Less than 10
[ ] 10-50
[ ] 51-250
[ ] 251-1000
[ ] More than 1000

A9. What is the turnover percentage rate among all employees on the payroll at this facility in the past 12 months?

Turnover rate [ ] %

☐ NA

A10. What is the turnover percentage rate among nurses on the payroll at this facility in the past 12 months?

Turnover rate [ ] %

☐ NA
A11. Are any employees on your payroll represented by unions?

☐ Yes
☐ No

A12. Is there a policy for working overtime at this facility? Note: Overtime may be defined as any hours worked in excess of the hours of a normal work shift, whether paid or unpaid for those excess hours. Please ✓ all that apply.

☐ Yes, established by management
☐ Yes, mandated by union contract
☐ No specific policy

A12A. Which of the following elements does the policy contain? Please ✓ all that apply.

☐ Mandatory overtime may be required
☐ Restrict the maximum number of overtime hours that can be worked per pay period
☐ Restrict the personnel that can be paid overtime
☐ Other (Please specify):_____________________

A13. Is there a policy for taking rest breaks at this facility? Please ✓ all that apply.

☐ Yes, established by management
☐ Yes, mandated by union contract
☐ No specific policy

A14. How many of the following professionals are on your payroll to provide health and safety services to employees at this facility on a full-time equivalency (FTE) basis?

<table>
<thead>
<tr>
<th>Professional</th>
<th>FTEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Occupational Physician</td>
<td></td>
</tr>
</tbody>
</table>
A15. Is there an individual on the payroll of this facility who has primary responsibility for managing the occupational safety program?

☐ Yes
☐ No ☒ Skip to Question A18.

A16. What proportion of the occupational safety program manager's time is spent specifically on occupational safety?

☐ 0-25%
☐ 26-50%
☐ 51-75%
☐ 76-100%

A17. To whom does the occupational safety program manager report?

☐ Chief Executive Officer
☐ Vice President
☐ Human Resources Director
☐ Facility Director
☐ Occupational Health Manager
☐ Other (Please specify): ________________

A18. Is there an individual on the payroll of this facility who has primary responsibility for managing the occupational or employee health program?

☐ Yes
☐ No ☒ Skip to Question A21.

A19. What proportion of the occupational or employee health program manager's time is spent specifically on occupational or employee health?

☐ 0-25%
☐ 26-50%
☐ 51-75%
☐ 76-100%

A20. To whom does the occupational or employee health manager report?

☐ Chief Executive Officer
☐ Vice President
☐ Human Resources Director
☐ Facility Director
☐ Occupational Safety Manager
☐ Other (Please specify): ________________

A21. During the past 12 months, which of the following occupational health and safety services have been provided at this facility by an outside source, (e.g., insurance carrier, private consultant, federal [NIOSH or OSHA] or state government, etc.)?

☐ Exposure Monitoring
☐ Employee Safety
☐ Ergonomics
☐ Occupational Health
☐ Other (Please specify): ________________
☐ None
The next few questions will be used to help assess the preparedness and capacity of your facility to respond to and treat victims during an emergency response to a natural disaster or terrorist incident.

A22. Does this facility have a formal emergency preparedness plan?  
☐ Yes  
☐ No — Skip to Question 27

A23. Which of the following mass casualty incidents does this facility's emergency preparedness plan specifically address? Please ✓ all that apply.  
☐ Natural disasters (e.g. flood, earthquake, hurricane)  
☐ Nuclear accident  
☐ Accident events (e.g. plane crashes, building collapses)  
☐ Terrorist use of biological agents  
☐ Terrorist use of chemical agents  
☐ Terrorist use of radiological agents  
☐ Influenza epidemics (e.g. Avian flu)  
☐ New emerging infections (e.g. SARS)  
☐ Other: Please specify ____________________________

A24. Does this facility have a coordinator responsible for all emergency preparedness efforts?  
☐ Yes  
☐ No

A25. Is this facility’s emergency preparedness plan integrated into the local (e.g. city, county, regional or state) emergency preparedness plan?  
☐ Yes  
☐ No

A26. Which of the following are addressed by this facility’s emergency preparedness plan? Please ✓ all that apply.  
☐ Processes to increase inpatient treatment capacity  
☐ Processes to increase outpatient treatment capacity  
☐ Stockpiling antibiotics and supplies  
☐ Designating mental health services (e.g. Critical Incident Stress Management) to care for employees, victims and their families, and others in the community who need special assistance coping with the consequences of a disaster  
☐ Mass immunization/prophylaxis  
☐ Ensuring adequate bio-protection (Universal Precautions) gear for facility personnel  
☐ Ensuring adequate food, linens and patient care items to enable 48-hour self-sufficiency  
☐ Access to portable cots, sheets, blankets, and pillows  
☐ Enhancing facility security by utilizing community law enforcement assets  
☐ Tracking expenses incurred during an emergency  
☐ Coordination with state or local public health authorities  
☐ Creating additional isolation beds  
☐ Facilities and equipment for decontaminating victims and/or facility personnel affected by chemical, biological, or radiological contaminant
A27. Does this facility provide staff training on emergency preparedness?

☐ Yes
☐ No → Skip to Question 29

A28. Which of the following personnel are provided training on emergency preparedness? Please ✓ all that apply.

☐ Physicians/Specialty medical staff
☐ Nursing staff
☐ Residents
☐ Students/Interns
☐ Administrative staff
☐ Laboratory staff
☐ Volunteer staff
☐ Security personnel
☐ Other: Please specify ______________________

A29. Does this facility have or participate in a tracking system to track trends or patients presenting problems or complaints?

☐ Yes
☐ No → Skip to Question 31

A30. Which of the following does this facility's surveillance system track? Please ✓ all that apply.

☐ ER visits
☐ Hospital admissions (total number and patterns)
☐ Presenting patients' complaints
☐ Influenza-like illness monitoring
☐ Increased antibiotic prescription rate
☐ Other: Please specify ______________________

The next few questions deal with health and safety programs

A31. Is there a written employee safety and health program in place at this facility?

☐ Yes
☐ No → Skip to Question A34.
A32. Which of the following elements are specifically included in the written employee health and safety (H&S) program at this facility? Please ✓ all that apply.

- Management leadership (top level management setting H&S policies and goals, active in H&S committees, etc.)
- Employee involvement (workers participating in H&S program planning and goal setting, H&S inspections, H&S committees, etc.)
- Safety Incentive Program (employees or work groups are rewarded for reducing accidents, offering safety suggestions, reporting hazards and near misses, and/or attending safety meeting)
- Job hazard analysis (identification of health and safety hazards associated with each job)
- Task analysis for proper selection of personal protective equipment
- Use of engineering, administrative, and personal protective equipment controls to eliminate or reduce occupational H&S hazards
- Regularly scheduled inspection and maintenance of engineering controls and personal protective equipment
- Providing H&S training to employees prior to assignment of job duties
- Procedures for employees to report health and safety problems without fear of reprisal
- Monitoring of workers for exposure to chemical, biological, and/or physical agents
- Medical surveillance of employees in high hazard jobs
- Routine worker notification of medical surveillance results
- Routine worker notification of exposure monitoring results
- Evaluation of H&S program effectiveness on periodic basis
- Policies to provide site-specific health and safety information for contractors’ employees prior to their beginning work at this facility
- Evaluation of contractors’ health and safety training provided to their employees prior to their assignment at this facility
A33. What data are used to evaluate the effectiveness of the employee health and safety program at this facility? Please ✓ all that apply.

- Injury and illness data
- Number of lost work-days
- Workers’ compensation data
- Number of “near-miss” accidents or incidents
- Number of employees who have completed mandatory training
- Average number of days to complete corrective action requests
- Training logs
- Knowledge tests
- Attitude scales
- Symptom surveys
- Observations from walk through inspections
- Cost-benefit data
- Other (Please specify): _______________________
- None, we do not evaluate our health and safety program

The next few questions pertain to occupational stress among employees.

A34. Have there been any employee complaints related to occupational stress reported in the past 12 months at this facility?

- Yes
- No complaints reported
- No formal reporting system is used

A35. Is stress management training available to all employees at this facility?

- Yes
- No

A36. Are employee assistance programs available to all employees at this facility?

- Yes
- No

The next few questions pertain to types of programs sometimes used to reduce the occurrence of acute or cumulative trauma resulting in back, shoulder, or other types of musculoskeletal injury.

A37. Has a written ergonomics program been implemented?

- Yes, in all areas
- Yes, in some areas
- No
Management Questionnaire

A38. Have teams of management and workers been formed at this facility to identify ergonomic risk factors?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No

A39. Has a job hazard analysis been conducted?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No

A40. Has an ergonomic training program been implemented at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No

A41. Are back belts available to affected employees for lifting tasks at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No

The next questions deal with devices and policies designed to help safeguard workers in performing physical tasks.

A42. Are adjustable work stations (tables, chairs, foot stands, etc.), available for employees performing stationary tasks at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No
   □ Task not performed

A43. Are wrist braces for repetitive upper extremity tasks, such as typing, pipetting, sonography, etc., available to affected employees at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No
   □ Task not performed

A44. Are anti-fatigue mats or sit/stand bars available in areas where tasks requiring prolonged standing are performed by employees at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No
   □ Task not performed

A45. At this facility, do employees ever lift or move patients weighing 50 or more pounds?
   □ Yes
   □ No [→ Skip to Question A51]

A46. Are transport carts and lift tables, or other assistive devices, available where necessary at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No

A47. Are mechanical lifting devices (e.g., Hoyer® lift) available in areas where patients are moved at this facility?
   □ Yes, in all areas
   □ Yes, in some areas
   □ No
A48. Has a "zero lift" policy been implemented at this facility, i.e., are mechanical lifting devices used exclusively for patient lifting?
- Yes, in all areas
- Yes, in some areas
- No

A49. Are organized lift teams used for lifting or transferring patients at this facility?
- Yes, in all areas
- Yes, in some areas
- No

A50. Are gait belts (or transfer belts) available for lifting or transferring patients at this facility?
- Yes, in all areas
- Yes, in some areas
- No

The following questions pertain to the issue of workplace violence at this facility.

A51. Are employees at this facility provided training in the skills necessary to defuse a potentially violent confrontation with patients, co-workers, supervisors, clients, family members, strangers, etc.?
- Yes, all workers
- Yes, only high risk workers
- No

A52. Do you have a formal program or policy in place at this facility for workers to report incidents of workplace violence?
- Yes
- No
- Don't Know

A53. How many incidents of workplace violence (physical attacks or assaults, verbal abuse, or confrontations) have been reported by employees at this facility during the last 12 calendar months?
- None
- 1-10
- 11-50
- 51-100
- More than 100 incidents
- Don't know

These next six questions ask about the use of natural rubber latex at your facility.

A54. Are any latex (natural rubber) products used anywhere in this facility?
- Yes
- No

A55. Are latex (natural rubber) gloves currently used anywhere in this facility?
- Yes, powdered latex gloves
- Yes, powder-free latex gloves
- Yes, both powdered latex and powder-free latex gloves
- No
A56. Is there a written policy in place at this facility to restrict unnecessary use of latex products?  □ Yes  □ No

A57. Are prevention strategies at this facility re-evaluated whenever a worker is diagnosed with latex allergy?  □ Yes  □ No

A58. Are employees provided training about latex allergies?  □ Yes  □ No

A59. Are high-risk workers (e.g., surgical staff) periodically screened for symptoms of latex allergy?  □ Yes  □ No

The next three questions ask about respirator usage at this facility.

A60. Are any employees at this facility required to wear respiratory protection for any reason? (Note: surgical masks are not considered respiratory protection for the user.)  □ Yes  □ No  → Skip to Section B on Page 12.

A61. Is training on respirator usage and maintenance provided to all employees who are required to wear respirators at this facility?  □ Yes  □ No

A62. Is fit testing required for all employees who are required to wear tight-fitting respiratory protection at this facility (exclude surgical masks and Powered Air-Purifying Respirators [PAPRs])?  □ Yes  □ No

The final question in this section asks about needlestick injuries.

A63. In the past calendar year, how many percutaneous needlestick injuries have been reported by employees at this facility?  No. of needlestick injuries reported: [___]

Thank you for completing Section A.  Please continue to Section B: Antineoplastic Agents on Page 12.
SECTION B: ANTINEOPLASTIC AGENTS

This section focuses on antineoplastic agents. The focus is on policies and procedures that apply to employees who prepare or mix these agents, such as pharmacists and pharmacy technicians, and employees who administer these drugs, including infusion nurses working with cancer, rheumatoid arthritis, and obstetrics patients. Other terms used for antineoplastic agents may include: antineoplastic drugs, cytotoxic drugs, and anti-cancer drugs.

B1. Are antineoplastic agents used at this facility?

- Yes
- No

B2. During the past week, how many doses of the following drugs were administered at this facility?

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Number of Doses</th>
<th>0</th>
<th>1-10</th>
<th>11-25</th>
<th>26-50</th>
<th>&gt;50</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Aldesleukin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Alemtuzumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Alitretinoin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Altretamine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Aminoglutethimide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f. Amifostine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>g. Anastrozole</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>h. Arsenic trioxide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>i. Asparaginase-E.coli strain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>j. BCG live</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>k. Bexarotine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>l. Bicalutamide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>m. Bleomycin (Bleo®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n. BNCU (Carmustine®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>o. Busulfan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p. Capecitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>q. Carboplatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>r. Choambucil (Leukeran®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>s. Cisplatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t. CPT-11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>u. Cladribine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>v. Cyclophosphamids (Cytoxan®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>w. Cytarbine (Cytosar®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>x. Daunorubicin (Carubicin®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>y. Dacarbazine (DTIC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>z. Dactinomycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aa. Denileukin dtftox</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bb. Docetaxel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>0</td>
<td>1-10</td>
<td>11-25</td>
<td>26-50</td>
<td>&gt;50</td>
<td>Drug Name</td>
</tr>
<tr>
<td>-----------</td>
<td>----</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>cc. Doxorubicin (Adriamycin&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>bbb. Methotrexate (Amethopterin&lt;sup&gt;®&lt;/sup&gt;)</td>
</tr>
<tr>
<td>dd. Epirubicin</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ccc. Mitomycin-C</td>
</tr>
<tr>
<td>ee. Estramustine</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ddd. Mitotane</td>
</tr>
<tr>
<td>ff. Etoposide</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>eee. Mitoxantrone</td>
</tr>
<tr>
<td>gg. Exemestane</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ff. Niutamida</td>
</tr>
<tr>
<td>hh. Flocuridine</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ggg. Pacitaxel</td>
</tr>
<tr>
<td>ii. Fludarabine</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>hhh. Pegaspargase</td>
</tr>
<tr>
<td>jj. Flutamide</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>iii. Pentostatin</td>
</tr>
<tr>
<td>kk. Fluorouracil (5-FU&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>jjj. Plicamycin</td>
</tr>
<tr>
<td>ll. Gemcitabine (Gemzar&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>kkk. Procarba-zine</td>
</tr>
<tr>
<td>mm. Gemtuzumab ozogamycin</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>lll. Rituximab</td>
</tr>
<tr>
<td>nn. Goserelin</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>mmm. Streptozocin</td>
</tr>
<tr>
<td>oo. Hydroxyurea</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>nnn. Tamoxifen</td>
</tr>
<tr>
<td>pp. Idarubicin</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ooo. Temozolo-mide</td>
</tr>
<tr>
<td>qq. Ifoephamide</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ppp. Teniposide</td>
</tr>
<tr>
<td>rr. Imatinib mesylate</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>qqq. Thioguanine</td>
</tr>
<tr>
<td>ss. Interferon Alfa-2a</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>rrr. Thiotepa</td>
</tr>
<tr>
<td>tt. Interferon Alfa-2b</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>sss. Topotecan</td>
</tr>
<tr>
<td>uu. Irinotecan</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>ttt. Toremifene</td>
</tr>
<tr>
<td>vv. Letrozole</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>uuu. Trastu-zumab</td>
</tr>
<tr>
<td>ww. Leuprolide</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>vvv. Tretinoin</td>
</tr>
<tr>
<td>xx. Megestrol</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td><a href="http://www">www</a>. Vairubicin</td>
</tr>
<tr>
<td>yy. Mercaptopurine (Leupurin&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>xxx. Vinblasione (Velban&lt;sup&gt;®&lt;/sup&gt;)</td>
</tr>
<tr>
<td>zz. Merclo-rethamine</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>yyy. Vincriistine (Oncovin&lt;sup&gt;®&lt;/sup&gt;)</td>
</tr>
<tr>
<td>aaa. Melphalan</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>zzz. Vinorelbine</td>
</tr>
<tr>
<td>Other (Please specify):</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>
The next two questions pertain to the number of male and female workers at this facility currently performing activities involving the handling of antineoplastic agents. If a worker performs more than one of the activities listed, please count this individual in each applicable category. Enter "0" for none.

B3. How many workers mix or prepare doses of antineoplastic agents? (These workers are usually pharmacists or pharmacy technicians.)

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2-5</th>
<th>6-10</th>
<th>11-20</th>
<th>&gt; 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Males</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B4. How many workers administer antineoplastic agents? (These workers are usually oncology/infusion nurses, or may also work in areas where patients are being treated for rheumatoid arthritis or ectopic pregnancies.)

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2-5</th>
<th>6-10</th>
<th>11-20</th>
<th>&gt; 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Males</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B5. Are there written standard procedures (SOPs) for any of the following activities? Please ✓ all that apply.

- Receipt and unpacking antineoplastic agents
- Mixing or preparing antineoplastic agents
- Administering antineoplastic agents
- Cleanup of spills of antineoplastic agents
- Handling bodily fluids (e.g., urine, stool, vomit, etc.) of patients receiving antineoplastic agents
- Disposal of AN-contaminated waste (empty vials, syringes, IV bags, absorbent pads, tubing, etc.)
### Management Questionnaire

**B6.** When do workers who perform the following activities receive training which addresses the safe handling and hazards of antineoplastic agents? Please **✓** all that apply.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Never</th>
<th>At job or task orientation</th>
<th>At least one or more times every 12 months</th>
<th>Other (Please specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Preparing antineoplastic agents</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>b. Administering antineoplastic agents</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>c. Any other activities with potential exposure to antineoplastic agents</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

**STOP** If training is **never** provided to any employee who handles antineoplastic agents, skip to Question B8.

**B7.** Is this training mandatory or voluntary?

- ☐ Mandatory
- ☐ Voluntary

**B8.** Has exposure monitoring (e.g., air sampling, surface wipe sampling, etc.) been performed in the past 12 months to assess workers' potential exposure to any antineoplastic agents at this facility?

- ☐ Yes
- ☐ No \[Skip to Question B9.\]

**B8A.** What type(s) of samples were collected? Please **✓** all that apply.

- ☐ Skin wipes
- ☐ Surface wipes
- ☐ Air samples \[Skip to Question B10.\]
B9. What are the reasons exposure monitoring has not been performed in the past 12 months at this facility to assess workers' exposure to any antineoplastic agents? Please √ all that apply.

☐ 1. Exposure to antineoplastic agents is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.

☐ 2. Exposure to antineoplastic agents is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.

☐ 3. Exposure to antineoplastic agents is felt to be insignificant based on the use of engineering controls.

☐ 4. Not required by OSHA.

☐ 5. Unaware of appropriate sampling methods for antineoplastic agents.


☐ 7. Too costly.

☐ 8. Other (Please specify): __________

B9A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason exposure monitoring has not been collected at this facility to assess workers' exposure to any antineoplastic agents.

Most important reason .......... 

B10. Is medical surveillance (such as medical questionnaire, physical exam, blood test, urine test) currently conducted for workers who handle, work with or are otherwise potentially exposed to antineoplastic agents?

☐ Yes

☐ No  →  Skip to Question B13.
B11. When are the following medical surveillance tests or exams provided to employees potentially exposed to antineoplastic agents? *(For each type of exam, enter a ✓ for each applicable time of administration).*

<table>
<thead>
<tr>
<th></th>
<th>Never</th>
<th>At pre-placement</th>
<th>Periodically</th>
<th>Following a needlestick</th>
<th>At job exit</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Standardized medical questionnaire..................</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
<tr>
<td>b. Physical exam..................</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
<tr>
<td>c. Blood test ..................</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
<tr>
<td>d. Urine test..................</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
</tbody>
</table>

B12. Are the results of these tests provided to affected employees?  
✓ Yes  
❑ No

If medical surveillance is conducted for all workers potentially exposed to antineoplastic agents, skip to Question B14.

B13. What are the reasons medical surveillance is not currently conducted for workers exposed to antineoplastic agents at this facility? *Please ✓ all that apply.*

❑ 1. Exposure to antineoplastic agents is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.

❑ 2. Exposure to antineoplastic agents is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.

❑ 3. Exposure to antineoplastic agents is felt to be insignificant based on the use of engineering controls.

❑ 4. Not required by OSHA.

❑ 5. Lack of health and safety personnel.

❑ 6. Too costly.

❑ 7. Other (Please specify): ___________________________

B13A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason medical surveillance has not been conducted for workers exposed to antineoplastic agents at this facility

Most important reason........... □
B14. Does this facility have a policy or procedures to inform high-risk employees (e.g. women or child-bearing potential, those with relevant pre-existing conditions, etc.) about potential exposure to antineoplastic agents?

- Yes
- No

Policies for Preparing Antineoplastic Agents

B15. Are antineoplastic agents prepared at this facility?

- Yes
- No

B16. Are antineoplastic agents required to be prepared in a restricted area, accessible only to personnel trained in the specific requirements associated with preparing these agents?

- Yes
- No

B17. Is consumption of food and beverages by employees prohibited in areas where antineoplastic agents are prepared?

- Yes
- No

B18. Are antineoplastic agents required to be mixed or prepared in either a Class II, Type B, or Class III Biological Safety Cabinet?

- Yes
- No

B19. Are antineoplastic agents required to be mixed using a closed drug transfer system?

- Yes
- No

B20. Are antineoplastic agents required to be mixed using a needle-less drug transfer system?

- Yes
- No

B21. Is the IV tubing used for delivering antineoplastic agents always required to be primed in a biological safety cabinet?

- Yes
- No

B22. After mixing, are antineoplastic agents required to be packaged for delivery to remote units in sealed and properly labeled bags?

- Yes
- No
Policies for Administering Antineoplastic Agents

B23. Are antineoplastic agents administered at this facility?
- Yes
- No  [Skip to Question B27.]

B24. Are antineoplastic agents required to be administered using a drug delivery system with Luer lock-type fittings?
- Yes
- No

B25. Are needle less drug transfer systems available at this facility for the administration of antineoplastic agents?
- Yes
- No

B26. Is the consumption of food and beverages by employees prohibited in areas in which antineoplastic agents are administered?
- Yes
- No

Policies for Designated Spill Clean-up Teams

B27. Which of the following spills of antineoplastic agents are cleaned up by specially trained spill clean-up personnel?
- None, do not use special spill team
- Small-sized spills (< 5cc)
- Medium-sized spills (5-25cc)
- Large spills (> 25cc)

Please ✓ all that apply
**Personal Protective Equipment/Clothing (PPE/C)**

**B28.** Please check the types of personal protective equipment/clothing (PPE) that are required for workers potentially exposed to antineoplastic agents in this facility. Please answer this for the following two activities for each of the types of PPE.

<table>
<thead>
<tr>
<th>Personal Protective Equipment (PPE) Type</th>
<th>Preparing antineoplastic agents</th>
<th>Administering antineoplastic agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Activity not performed at this facility .......</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>b. None are required ..........................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>c. Single-use, disposable gown with closed front and tight cuffs ...............................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>d. Laundered protective garment (e.g., lab coat, scrubs, apron, etc.) ........................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>e. Chemotherapy &quot;chemo&quot; gloves (of any type of material) ...........................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>f. Natural rubber latex gloves, excluding &quot;chemo&quot; gloves ...................................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>g. Non-latex gloves, excluding &quot;chemo&quot; gloves ..................................................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>h. Two pairs of gloves (&quot;double glove&quot;) .........</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>i. Eye protection (e.g., face shield, splash goggles, or safety glasses) ........................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>j. Disposable particulate respirator (also called filtering facepiece respirator, e.g., N95) ..............</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>k. Elastomeric half-mask or full-facepiece respirator with replaceable cartridges ...........................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>l. Powered air purifying respirator (PAPR) ....</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>m. Supplied air respirator ..............................................................................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>n. Other respirator (excluding surgical mask) ....................................................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>o. Disposable booties ........................................................................................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>p. Other PPE/C (Please specify) ..........................................................................................................</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
Management Questionnaire

B39. Does this facility have a policy which prohibits taking home any clothing (protective clothing or street clothes) which were worn when...

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a. Preparing antineoplastic agents? ........

b. Administering antineoplastic agents? ...

Thank you for completing Section B. Please continue to Section C: Aerosolized Medications on Page 22.
SECTION C: AEROSOLIZED MEDICATIONS

This section focuses on aerosolized ribavirin (Virazole®), pentamidine (Nebupent®), and tobramycin (Nebcin®). The focus is on policies and procedures that apply to respiratory therapists and others who administer or otherwise handle these medications.

C1. Is aerosolized ribavirin, pentamidine, or tobramycin used at this facility?

☐ Yes
☐ No  ➡️  Skip to Section D on Page 27.

C2. During the past month, how many doses of the following drugs were administered at this facility? Check "0" for none.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>0</th>
<th>1-10</th>
<th>11-25</th>
<th>26-50</th>
<th>&gt;50</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Aerosolized Ribavirin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Aerosolized Pentamidine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Aerosolized Tobramycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The next questions pertain to the number of male and female workers at this facility currently administering aerosolized ribavirin, pentamidine or tobramycin.

C3. How many workers at this facility currently administer aerosolized ribavirin, pentamidine and/or tobramycin?

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2-5</th>
<th>6-10</th>
<th>11-20</th>
<th>&gt; 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Males</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C4. When do workers who administer ribavirin, pentamidine and/or tobramycin receive training which addresses the hazards and safe handling of any of these aerosolized medications? Please ✓ all that apply.

☐ Never  ➡️  Skip to Question C6.
☐ At job or task orientation
☐ At least annually, i.e. one or more times every 12 months
☐ Other (Please specify): ____________________________

C5. Is this training mandatory or voluntary?

☐ Mandatory
☐ Voluntary

C6. Has exposure monitoring (e.g., air sampling, surface wipe sampling, etc.) been performed in the past 12 months to assess workers’ potential exposure to ribavirin, pentamidine or tobramycin (any or all) at this facility?

☐ Yes  ➡️  Skip to Question C8.
☐ No
C7. What are the reason(s) exposure monitoring has *not* been performed in the past 12 months at this facility to assess workers' exposure to any of these aerosolized medications? Please ✓ all that apply.

- 1. Exposure to aerosolized medications is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.
- 2. Exposure to aerosolized medications is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.
- 3. Exposure to aerosolized medications is felt to be insignificant based on the use of engineering controls.
- 4. Not required by OSHA.
- 5. Unaware of appropriate sampling methods for aerosolized medications.
- 6. Lack of health and safety personnel.
- 7. Too costly.
- 8. Other (Please specify): ____________

Most important reason: _________

C7A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason exposure monitoring *has* not been performed at this facility to assess workers' exposure to any aerosolized medications.

C8. Is medical surveillance (such as medical questionnaire, physical exam, blood test, urine test, pulmonary function test) currently conducted for workers potentially exposed to ribavirin, pentamidine or tobramycin?

- Yes
- No  ➡ Skip to Question C12.

C9. When are the following medical surveillance tests or exams provided to employees potentially exposed to aerosolized ribavirin, pentamidine or tobramycin (any or all)?

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Never</th>
<th>At Pre-placement</th>
<th>Periodically</th>
<th>At Job exit</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Standardized medical questionnaire</td>
<td>✗</td>
<td>✗</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Physical exam</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td></td>
</tr>
<tr>
<td>c. Blood tests</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>d. Urine tests</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>e. Pulmonary function test</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>
C10. Are the results of these medical surveillance tests provided to affected employees?

☐ Yes
☐ No

STOP

If medical surveillance is currently conducted for all employees exposed to aerosolized medications, Skip to Question C12.

C11. What are the reasons medical surveillance is not currently conducted for all workers exposed to these aerosolized medications at this facility? Please ✓ all that apply.

☐ 1. Exposure to aerosolized medications is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.

☐ 2. Exposure to aerosolized medications is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.

☐ 3. Exposure to aerosolized medications is felt to be insignificant based on the use of engineering controls.

☐ 4. Not required by OSHA.

☐ 5. Lack of health and safety personnel.

☐ 6. Too costly.

☐ 7. Other (Please specify): ________________________

Most important reason __________

C11A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason medical surveillance has not been conducted for all workers exposed to these aerosolized medications at this facility.
C12. Does this facility have a policy or procedures to identify/screen employees about pregnancy (planning or currently pregnant) and potential exposure to these aerosolized medications?

☐ Yes
☐ No

C13. In this facility, which of the following work practices or engineering controls are required during administration of these aerosolized medications? Please ✔ all that apply.

☐ Oxygen tent.
☐ Double containment system (i.e., HEPA filtered oxygen tent over oxygen hood).
☐ Mechanical ventilator equipped with exhalation filter.
☐ Nebulizer or aerosol generator equipped with exhalation filter.
☐ HEPA-filtered isolation chamber/booth/hood.
☐ Negative pressure isolation rooms with ventilation system equipped with HEPA filters or direct exhaust to the outdoors.
☐ Restrict non-essential employee access during and immediately following (within 30 minutes) administration of aerosolized medications.
☐ Clean the surfaces of the nebulizer prior to moving it to another location.
☐ Special procedures for cleaning rooms after administration of aerosolized medications.
☐ Other (Please specify): _______________________

☐ None
C14. Which types of Personal Protective Equipment (PPE) are required for employees while they are administering ribavirin, pentamidine and/or tobramycin at this facility? Please ✓ all that apply. (Please do not include surgical masks as respiratory protection.)

- Protective gown or garment
- Protective gloves
- Eye protection (e.g., face shield, splash goggles, or safety glasses)
- Disposable particulate respirator (also called filtering face-piece respirator, e.g., N95)
- Elastomeric half-mask or full-face-piece respirator with replaceable filters or cartridges
- Powered air purifying respirator (PAPR)
- Disposable booties
- Other (Please specify): __________________

C15. Does this facility have a policy which prohibits taking home any clothing (protective clothing or street clothes) which were worn while administering ribavirin, pentamidine and/or tobramycin?

- Yes
- No

Thank you for completing Section C.
Please continue to Section D: Glutaraldehyde and Other High Level Disinfectants (HLDs) on page 27.
SECTION D: GLUTARALDEHYDE AND OTHER HIGH LEVEL DISINFECTANTS (HLDs)

This module is directed towards anyone who disinfects medical instruments, devices, or supplies (such as endoscopes, thermometers, and other items which cannot be sterilized) using disinfectants containing the following:

- **Glutaraldehyde** (e.g., Cidex®, ColdSport®, Endocide®, Glutacide®, Hospex®, Metricide®, Sporicidin®, Wavicide®),
- **Ortho-phthalaldehyde** (e.g., Cidex OPA®),
- **Peracetic acid** (e.g., Steris® system), or
- **Hydrogen peroxide** (e.g., Accell®, Optim®).

D1. Are HLDs used at this facility?  
☐ Yes  
☐ No  
→ Skip to Section E on Page 34.

D2. Are HLDs used to disinfect endoscopes or other medical instruments and devices at this facility?  
☐ Yes  
☐ No  
→ Skip to Question D28.

D3. Is glutaraldehyde used to disinfect endoscopes or other medical instruments and devices at this facility?  
☐ Yes  
☐ No  
→ Skip to Question D13.

D4. How many workers at this facility currently use glutaraldehyde to disinfect medical instruments?  
☐ 1  
☐ 2-5  
☐ 6-10  
☐ 11-20  
☐ > 20

D5. Are there written standard procedures for the safe handling of glutaraldehyde for disinfection at this facility?  
☐ Yes  
☐ No

D6. When do workers who use glutaraldehyde to disinfect medical instruments receive training from this employer which addresses the hazards and safe handling of this HLD?  
☐ Never  
☐ At job or task orientation  
☐ At least annually (i.e., one or more times in 12 months)  
☐ Other (Please specify): ____________

D7. Have air samples been collected in the past 12 months to assess worker exposure to glutaraldehyde at this facility?  
☐ Yes  
☐ No  
→ Skip to Question D9.
D8. What are the reasons air samples have not been collected in the past 12 months at this facility to assess workers' exposure to glutaraldehyde? Please ✓ all that apply.

☐ 1. Exposure to glutaraldehyde is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.

☐ 2. Exposure to glutaraldehyde is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.

☐ 3. Exposure to glutaraldehyde is felt to be insignificant based on the use of engineering controls.

☐ 4. Not required by OSHA.

☐ 5. Unaware of appropriate sampling methods for glutaraldehyde.


☐ 7. Too costly.

☐ 8. Other (Please specify): __________

D8A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason air samples have not been collected at this facility to assess workers' exposure to glutaraldehyde.

Most important reason........... [ ]

D9. Is medical surveillance (such as medical questionnaire, physical exam, pulmonary function test, allergy/sensitization test) currently conducted for workers who use glutaraldehyde to disinfect medical instruments?

☐ Yes

☐ No → Skip to Question D12.

D10. When are the following medical surveillance tests or exams provided to employees potentially exposed to glutaraldehyde? Please ✓ all that apply.

<table>
<thead>
<tr>
<th></th>
<th>Never</th>
<th>At pre-placement</th>
<th>Periodically</th>
<th>Following an acute exposure (e.g., a spill)</th>
<th>At job exit</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Standardized medical questionnaire</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>b. Physical exam</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>c. Pulmonary function test</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>d. Allergy/sensitization test</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>
D11. Are results of these medical surveillance tests provided to affected employees?

☐ Yes
☐ No

If medical surveillance is conducted for all workers potentially exposed to glutaraldehyde, Skip to Question D13.

D12. What are the reasons medical surveillance is not currently conducted at this facility for workers exposed to glutaraldehyde? Please ✓ all that apply.

☐ 1. Exposure to glutaraldehyde is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.
☐ 2. Exposure to glutaraldehyde is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.
☐ 3. Exposure to glutaraldehyde is felt to be insignificant based on the use of engineering controls.
☐ 4. Not required by OSHA.
☐ 5. Lack of health and safety personnel.
☐ 6. Too costly.
☐ 7. Other (Please specify): ____________

D12A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason medical surveillance has not been conducted for workers exposed to glutaraldehyde at this facility.

Most important reason......... □

D13. Has ortho-phthalaldehyde, peracetic acid or hydrogen peroxide been substituted for glutaraldehyde as a high level disinfectant? (i.e., switch to Cidex OPA®, Steris® system, Accel®, or Optim® from Cidex®, ColdSport®, Endocide®, Glutacide®, Hopsex®, MetriCide®, Sporicidin®, Wavicide®)

☐ Yes, in all cases
☐ Yes, in some cases
☐ No ➔ Skip to Question D14.

D13A. What was the primary reason for the substitution? Please ✓ only one.

☐ Recommendation from supplier
☐ Improve worker health and safety conditions
☐ Reduce regulatory concerns
☐ Reduce cost
☐ Other (Please specify): ____________
D14. Is ortho-phthalaldehyde used to disinfect medical instruments at this facility?  
☐ Yes  
☐ No  
Skip to Question D18.

D15. How many workers at this facility currently use ortho-phthalaldehyde to disinfect medical instruments?  
☐ 1  
☐ 2-5  
☐ 6-10  
☐ 11-20  
☐ 21-50  
☐ >50

D16. Are there written standard procedures for the safe handling of ortho-phthalaldehyde for disinfection at this facility?  
☐ Yes  
☐ No

D17. When do workers who use ortho-phthalaldehyde to disinfect medical instruments receive training from this employer which addresses the hazards and safe handling of this HLD? Please ✓ all that apply.  
☐ Never  
☐ At job or task orientation  
☐ At least annually (i.e., one or more times in 12 months)  
☐ Other (Please specify): _______________

D18. Is peracetic acid used to disinfect medical instruments at this facility?  
☐ Yes  
☐ No  
Skip to Question D22.

D19. How many workers at this facility currently use peracetic acid to disinfect medical instruments via immersion processing techniques?  
☐ 1  
☐ 2-5  
☐ 6-10  
☐ 11-20  
☐ 21-50  
☐ >50

D20. Are there written standard procedures for the safe handling of peracetic acid for disinfection at this facility?  
☐ Yes  
☐ No

D21. When do workers who use peracetic acid to disinfect medical instruments receive training from this employer which addresses the hazards and safe handling of this HLD? Please ✓ all that apply.  
☐ Never  
☐ At job or task orientation  
☐ At least annually (i.e., one or more times in 12 months)  
☐ Other (Please specify): _______________
D22. Is hydrogen peroxide used to disinfect medical instruments via immersion processing techniques at this facility?

- Yes
- No [Skip to Question D26.]

D23. How many workers at this facility currently use hydrogen peroxide to disinfect medical instruments via immersion processing techniques?

- 1
- 2-5
- 6-10
- 11-20
- > 20

D24. Are there written standard procedures for the safe handling of hydrogen peroxide for disinfection at this facility?

- Yes
- No

D25. When do workers who use hydrogen peroxide to disinfect medical instruments receive training from this employer which addresses the hazards and safe handling of this HLD? Please ✔ all that apply.

- Never
- At job orientation
- At least annually (i.e., one or more times in 12 months)
- Other (Please specify): ________________

The next few questions refer to any of the four specific high level disinfectants (i.e., glutaraldehyde, ortho-phthalaldehyde, paracetic acid, and hydrogen peroxide) previously addressed in this module.

D26. Have any equipment modifications or procedural changes been made for the primary purpose of reducing worker exposure to high level disinfectants?

- Yes
- No [Skip to Question D27.]

D26A. What was the nature of these equipment modifications or procedural changes? Please ✔ all that apply.

- Use of automated, enclosed disinfection systems which are ventilated
- Use of covered or ventilated disinfection trays/bins
- Centralize high level disinfectants stations into fewer locations
- Use of a closed system for transferring high level disinfectants
- Other (Please specify): ________________
D27. Please check the types of personal protective equipment/clothing that **are required** for workers potentially exposed to high level disinfectants in this facility. Please answer for the following four high level disinfectants and for each of the types of PPE. *(Check the boxes in part “a” if the particular product is not used, and check the boxes in part “b” if no personal protective equipment is required for employees working with a particular disinfectant.)*

<table>
<thead>
<tr>
<th>Personal Protective Equipment (PPE) Type</th>
<th>Glutaraldehyde for disinfection</th>
<th>Orthophthalaldehyde for disinfection</th>
<th>Peracetic acid for disinfection</th>
<th>Hydrogen peroxide for disinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. This HLD is not used at this facility</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>b. None are required</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>c. Protective gown or garment</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>d. Protective gloves (non-fabric)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>e. Eye protection (e.g., face shield, splash goggles, or safety glasses)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>f. Elastomeric half-mask or full-facepiece respirator with replaceable cartridges</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>g. Powered air purifying respirator (PAPR)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>h. Other respirator (excluding surgical mask)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>i. Other PPE (Please specify):</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

D28. Are glutaraldehyde-containing solutions used for tissue fixation processes at this facility?

☐ Yes ☐ No [Skip to Question D30.]

D29. How many workers at this facility currently use glutaraldehyde for tissue fixation processes?

☐ 1 ☐ 2-5 ☐ 6-10 ☐ 11-20 ☐ > 20
D30. Are glutaraldehyde-containing solutions used for X-ray processing at this facility?

- Yes
- No    

Skip to Section E on Page 34.

D31. How many workers at this facility currently use glutaraldehyde for X-ray processing?

- 1
- 2-5
- 6-10
- 11-20
- > 20

Thank you for completing Section D. Please continue to Section E: Chemical Sterilants on page 34.
SECTION E: CHEMICAL STERILANTS

This section focuses only on ethylene oxide and hydrogen peroxide gas plasma (e.g., the STERRAD® system). It excludes steam sterilizers and autoclaves. The focus of this section is on policies and procedures that apply to central processing employees or others who sterilize medical instruments or supplies using chemical sterilants.

E1. Are chemical sterilants (either ethylene oxide or hydrogen peroxide gas plasma) used at this facility?
   - Yes
   - No  [Skip to Section F on Page 40.]

E2. Are there written standard procedures (for the safe handling of chemical sterilants at this facility?)
   - Yes
   - No

E3. When do workers who work with chemical sterilants receive training from this employer which addresses the hazards and safe handling of these materials? Please ✓ all that apply.
   - Never
   - At job or task orientation
   - At least annually (i.e., one or more times in 12 months)
   - Other (Please specify): __________________

E4. Does this facility currently use ethylene oxide to sterilize medical instruments or supplies?
   - Yes
   - No  [Skip to Question E14.]

E5. During the past week, what was the approximate number of loads sterilized using ethylene oxide at this facility?
   - 0
   - 1-10
   - 11-20
   - 21-50
   - >50

E6. How many workers at this facility currently sterilize medical instruments or supplies using ethylene oxide?
   - 0  1  2-5  6-10  11-20  > 20
   a. Males
   b. Females
E7. Have air samples (personal samples or fixed location area samples) been collected in the past 12 months to assess worker exposure to ethylene oxide?

☐ Yes, only personal samples → Skip to Question E10.
☐ Yes, only fixed location monitors
☐ Yes, both personal samples and fixed location monitors
☐ No

E8. What are the reasons air samples have not been collected in the past 12 months to assess workers' exposure to ethylene oxide? Please ✔ all that apply.

☐ 1. Exposure to ethylene oxide is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.
☐ 2. Exposure to ethylene oxide is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.
☐ 3. Exposure to ethylene oxide is felt to be insignificant based on the use of engineering controls.
☐ 4. Not required by OSHA.
☐ 5. Lack of appropriate sampling methods for ethylene oxide.
☐ 7. Too costly
☐ 8. Other (Please specify): ____________________________

Most important reason: ____________

E8A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason air samples have not been collected at this facility to assess workers' exposure to ethylene oxide.

E9. Where are the fixed location monitors located? Please ✔ all that apply.

☐ Adjacent to sterilizer loading door
☐ In immediate area where in-service ethylene oxide tanks are located
☐ Other (Please specify): ____________________________

E10. Is medical surveillance (such as medical questionnaire, physical exam, blood test) currently conducted for all workers who use ethylene oxide to disinfect medical instruments?

☐ Yes
☐ No → Skip to Question E13.
E11. When are the following medical surveillance tests or exams provided to employees at this facility who are potentially exposed to ethylene oxide? Please √ all that apply or never.

<table>
<thead>
<tr>
<th>Test Description</th>
<th>Never</th>
<th>At pre-placement</th>
<th>Periodically</th>
<th>After an acute exposure (i.e., a release)</th>
<th>At job exit</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Standardized medical questionnaire</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
<tr>
<td>b. Physical exam</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
<tr>
<td>c. Blood tests</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
<td>❑</td>
</tr>
</tbody>
</table>

E12. Are results of these tests provided to employees?  

[ ] Yes  [ ] No  

Skip to Question E14.

E13. What are the reasons medical surveillance is not currently conducted for all workers exposed to ethylene oxide at this facility? Please √ all that apply.

[ ] 1. Exposure to ethylene oxide is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.

[ ] 2. Exposure to ethylene oxide is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.

[ ] 3. Exposure to ethylene oxide is felt to be insignificant based on the use of engineering controls.

[ ] 4. Not required by OSHA.

[ ] 5. Lack of health and safety personnel.

[ ] 6. Too costly.

[ ] 7. Other (Please specify): __________________________

E13A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason medical surveillance has not been conducted for all workers' exposed to ethylene oxide at this facility.

Most important reason..........[ ]
E14. Are any of the following engineering controls or work practices required when ethylene oxide is used for sterilization at this facility?

- Use a combination sterilizer/aerator unit (i.e., where manual transfer of load between sterilizer and aerator is unnecessary)

- Sterilizer located in a separately enclosed room

- Aerator located in a separately enclosed room

- Other (Please specify):

   Yes  No

E15. Does this facility currently use hydrogen peroxide gas plasma (e.g., STERRAD® system) to sterilize medical instruments or supplies?

- Yes
- No  Skip to Question E21.

E16. During the past week, what was the approximate number of loads sterilized using hydrogen peroxide gas plasma at this facility?

- 0
- 1-10
- 11-20
- 21-50
- >50

E17. How many workers at this facility currently sterilize medical instruments or supplies using hydrogen peroxide gas plasma?

- 0
- 1
- 2-5
- 6-10
- 11-20
- > 20

E18. Is the hydrogen peroxide gas plasma sterilizer(s) located in a separately enclosed room?

- Yes, in all areas
- Yes, in some areas
- No

E19. Is hydrogen peroxide gas plasma (e.g., the STERRAD® system) used in place of ethylene oxide for chemical sterilization at this facility?

- Yes
- No  Skip to Question E21.
E20. What are the reasons you have chosen to use hydrogen peroxide gas plasma instead of ethylene oxide for chemical sterilization? Please ✓ all that apply.

☐ 1. Employee health and safety
☐ 2. Reduced sterilization cycle time
☐ 3. Reduced regulatory burden
☐ 4. Recommendation from vendor
☐ 5. Company mandate
☐ 6. Cost factors
☐ 7. Other (Please specify): 

E20A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason that you have decided to use hydrogen peroxide gas plasma instead of ethylene oxide for chemical sterilization.

Most important reason: [ ]

E21. Please check the types of personal protective equipment/clothing that are required for workers potentially exposed to chemical sterilants in this facility. Please answer this for the following two types of sterilants for each of the types of PPE.

<table>
<thead>
<tr>
<th>Personal Protective Equipment (PPE) Type</th>
<th>Using ethylene oxide</th>
<th>Using hydrogen peroxide plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Sterilant not used at this facility</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>b. None are required (SKIP TO Question E21)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>c. Single-use, disposable gown</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>d. Laundered protective garment (e.g., lab coat, scrubs, apron, etc.)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>e. Protective gloves, non fabric</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>f. Eye protection (e.g., face shield, splash goggles, or safety glasses)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>g. Respiratory protection (e.g., half or full face piece respirator with replaceable filters or cartridges, powered air-purifying respirator, or supplied air respirator—do not include surgical masks as respiratory protection)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>i. Other PPE (Please specify):</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
E22. Does this facility currently use gamma radiation to sterilize medical instruments/supplies?

☐ Yes
☐ No → Skip to Section F on Page 40

E23. How many workers at this facility currently sterilize medical instruments or supplies using gamma radiation?

☐ 0
☐ 1
☐ 2-5
☐ 6-10
☐ 11-20
☐ > 20

Thank you for completing Section E.
Please continue to Section F: Waste Anesthetic Gases on page 40.
SECTION F: WASTE ANESTHETIC GASES

This section focuses on the use and control of anesthetic gases. The focus is on policies and procedures that apply to employees working in areas such as operating rooms, PACU, emergency rooms, labor and delivery rooms, dental clinics and other areas where exposure to waste anesthetic gases is possible. Anesthetic gases include nitrous oxide, enflurane, desflurane, halothane, isoflurane, sevoflurane, and others.

F1. Are anesthetic gases used at this facility?  
☐ Yes  
☐ No  

Skip to Section G on Page 45.

F2. Have any of the following anesthetic agents been used at this facility during the past week (i.e., the past 7 calendar days)?

<table>
<thead>
<tr>
<th>Name of Anesthetic Agent</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Nitrous Oxide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Enflurane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Desflurane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Halothane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Isoflurane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>f. Sevoflurane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>g. Other (Please specify):</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F3. In the past week, what was the approximate amount of the following anesthetic agents used at this facility?

<table>
<thead>
<tr>
<th>Name of Anesthetic Agent</th>
<th>Amount Used (in liters)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td>a. Nitrous Oxide</td>
<td></td>
</tr>
<tr>
<td>b. Enflurane</td>
<td></td>
</tr>
<tr>
<td>c. Desflurane</td>
<td></td>
</tr>
<tr>
<td>d. Halothane</td>
<td></td>
</tr>
<tr>
<td>e. Isoflurane</td>
<td></td>
</tr>
<tr>
<td>f. Sevoflurane</td>
<td></td>
</tr>
<tr>
<td>g. Other (Please specify):</td>
<td></td>
</tr>
</tbody>
</table>
### Management Questionnaire

**F4.** What is the approximate number of male and female workers at this facility who routinely work in each of the following areas?

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. Operating rooms or induction rooms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>1-10</td>
<td></td>
<td>1-10</td>
</tr>
<tr>
<td>11-20</td>
<td></td>
<td>11-20</td>
</tr>
<tr>
<td>21-30</td>
<td></td>
<td>21-30</td>
</tr>
<tr>
<td>31-40</td>
<td></td>
<td>31-40</td>
</tr>
<tr>
<td>41-75</td>
<td></td>
<td>41-75</td>
</tr>
<tr>
<td>&gt;75</td>
<td></td>
<td>&gt;75</td>
</tr>
</tbody>
</table>

| **b. Recovery areas, including the PACU and labor and delivery rooms** |         |         |
| 0                    |         | 0       |
| 1-10                 |         | 1-10    |
| 11-20                |         | 11-20   |
| 21-30                |         | 21-30   |
| 31-40                |         | 31-40   |
| >40                  |         | >40     |

| **c. Emergency rooms** |         |         |
| 0                    |         | 0       |
| 1-10                 |         | 1-10    |
| 11-20                |         | 11-20   |
| 21-30                |         | 21-30   |
| 31-40                |         | 31-40   |
| >40                  |         | >40     |

| **d. All other areas where anesthetic gases may be administered** |         |         |
| 0                    |         | 0       |
| 1-10                 |         | 1-10    |
| 11-20                |         | 11-20   |
| 21-30                |         | 21-30   |
| 31-40                |         | 31-40   |
| >40                  |         | >40     |

**F5.** Are there written standard procedures for the safe handling of anesthetic agents at this facility?

- Yes
- No
F6. When do workers with the following responsibilities receive training which addresses the safe handling of anesthetic agents? Please ✓ all that apply.

<table>
<thead>
<tr>
<th>At job or task</th>
<th>At least annually, i.e., one or more times every 12 months</th>
<th>Other (Please specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Never</td>
<td>orientation</td>
</tr>
</tbody>
</table>

a. Administer anesthetic agents to patients ............

b. Work in areas where exposure to waste anesthetic agents is possible (e.g., areas where agents are being administered or in post anesthesia care areas). ......

F7. Have air samples been collected in the past 12 months to assess worker exposure to any waste anesthetic gases at this facility?

- ☐ Yes [Skip to Question F9.]
- ☐ No

F8. What are the reasons air samples have not been collected in the past 12 months at this facility to assess workers' exposure to any waste anesthetic gases? Please ✓ all that apply.

- ☐ 1. Exposure to waste anesthetic gases is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings
- ☐ 2. Exposure to waste anesthetic gases is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.
- ☐ 3. Exposure to waste anesthetic gases is felt to be insignificant based on the use of engineering controls.
- ☐ 4. Not required by OSHA.
- ☐ 5. Unaware of appropriate sampling methods for waste anesthetic gases.
- ☐ 6. Lack of health and safety personnel.
- ☐ 7. Too costly.
- ☐ 8. Sampling is too difficult in sterile areas.
- ☐ 9. Other (Please specify): ____________________

F8A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason air samples have not been collected at this facility to assess workers' exposure to waste anesthetic gases.

Most important reason ........... □
Management Questionnaire

F9. Is medical surveillance (such as medical questionnaire or physical exam) currently conducted for workers who perform the following activities involving waste anesthetic gases?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Administering anesthetic gases</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>b. Work in areas where exposure to waste anesthetic gases is possible</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

STOP If medical surveillance is not conducted on any employees with potential exposure to waste anesthetic gases, skip to Question F12.

F10. When are the following medical surveillance tests or exams provided to employees potentially exposed to waste anesthetic gases? Please ✓ all that apply.

<table>
<thead>
<tr>
<th></th>
<th>Never</th>
<th>At pre-placement</th>
<th>Periodically</th>
<th>At job exit</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Standardized medical questionnaire</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>b. Physical exam</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>c. Blood tests</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

F11. Are results of these tests provided to affected employees?

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

STOP If medical surveillance is conducted for all workers potentially exposed to waste anesthetic gases, skip to Question F13.
F12. What are the reasons medical surveillance is not currently conducted for workers exposed to waste anesthetic gases at this facility? Please ✓ all that apply.

☐ 1. Exposure to waste anesthetic gases is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.
☐ 2. Exposure to waste anesthetic gases is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.
☐ 3. Exposure to waste anesthetic gases is felt to be insignificant based on the use of engineering controls.
☐ 4. Not required by OSHA.
☐ 5. Lack of health and safety personnel.
☐ 6. Too costly.
☐ 7. Other (Please specify): __________________

Most important reason .......... _____________

F12A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason medical surveillance has not been conducted for workers exposed to waste anesthetic gases at this facility.

F13. In this facility, is a gas scavenging system always required during administration of anesthetic gases?

☐ Yes
☐ No

F14. Please check the types of personal protective equipment/clothing that are required for workers potentially exposed to waste anesthetic gases at this facility. Please ✓ all that apply.

☐ None are required
☐ Single-use disposable gown
☐ Laundered protective garment (e.g., lab coat, scrubs, apron, etc.)
☐ Protective gloves, non-fabric
☐ Eye protection (e.g., face shield, splash goggles, or safety glasses)
☐ Respiratory protection (e.g., half or full face-piece respirator with replaceable cartridges, powered air-purifying respirator, or supplied-air respirator-do not include surgical masks as respiratory protection)
☐ Other PPE (Please specify): __________________

Thank you for completing Section F.
Please continue to Section G: Surgical Smoke from Lasers or Electrosurgery Devices on page 45.
SECTION G: SURGICAL SMOKE FROM LASERS OR ELECTROSURGERY DEVICES

This section focuses on surgical smoke. Surgical smoke refers to emissions created by thermal destruction of tissue using lasers or electrosurgery devices. The focus is on policies and procedures applying to employees who work in operating rooms, emergency rooms, dermatology clinics, dental operatories or other areas where laser or electrosurgery devices are used.

G1. Are lasers or electrosurgical devices used at this facility?
   - Yes
   - No ➔ Skip to Section H on Page 48.

G2. How many workers at this facility currently use lasers or electrosurgical devices in surgical procedures or work in proximity (i.e., within 5 feet) to where these devices are being used by others?
   - 1
   - 2-10
   - 11-25
   - 26-50
   - > 50

G3. When do workers who use lasers or electrosurgery devices in surgical procedures receive training which addresses the hazards of surgical smoke? Please ✓ all that apply.
   - Never
   - At job or task orientation
   - At least annually (i.e., one or more times every 12 months)
   - Other (Please specify): ____________

G4. Have air samples been collected in the past 12 months to assess workers' exposure to surgical smoke?
   - Yes ➔ Skip to Question G6.
   - No
G5. What are the reasons air samples have not been collected in the past 12 months at this facility to assess workers’ exposure to surgical smoke? Please ✓ all that apply.

- 1. Exposure to surgical smoke is felt to be insignificant based on historical and/or objective data from industry studies for similar work settings.
- 2. Exposure to surgical smoke is felt to be insignificant based on previous sampling (more than 12 months ago) at this facility.
- 3. Exposure to surgical smoke is felt to be insignificant based on the use of engineering controls.
- 4. Not required by OSHA.
- 5. Unaware of appropriate sampling methods for surgical smoke.
- 6. Lack of health and safety personnel.
- 7. Too costly.
- 8. Sampling is too difficult in sterile areas.
- 9. Other (Please specify): ______________________

G5A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason air samples have not been collected at this facility to assess workers’ exposure to surgical smoke.

Most important reason............. □

G6. Is local exhaust ventilation (e.g., smoke evacuator/filtration device, room suction system) designed to remove the smoke plumes at the surgical site required at this facility when lasers or electrosurgical devices are being used?

- Yes, always
- Yes, sometimes
- No □ [Skip To Question G9.]

G7. How often is the smoke evacuation system required to be inspected to prevent possible leaks?

- As determined by the operator
- Before each procedure
- Once a week
- Once a month
- Other (Please specify): ______________________
G8. How often are new filters required to be installed in the smoke evacuation system?

☐ As determined by the operator
☐ Per manufacturer's instructions
☐ Before each procedure
☐ Once a week
☐ Once a month
☐ Other (Please specify): ______________________

G9. Please check the type(s) of personal protective equipment/clothing that are always required for employees exposed to surgical smoke in this facility. (This includes employees operating lasers or electrosurgery devices and all others working in the same room within 5 feet of the operation. Please do not include a surgical mask as respiratory protection.)

☐ a. Personal protective equipment is not required.............................................................

☐ b. Disposable particulate respirator (also called filtering face piece respirator, e.g., N95)........

☐ c. Elastomeric half-mask or full-facepiece respirator with replaceable cartridges..............

☐ d. Powered air purifying respirator (PAPR)............

☐ e. Supplied air respirator.....................................................

☐ f. Other respirator (excluding surgical mask)........

☐ g. Other PPE (Please specify): ______________________

---

Thank you for completing Section G. Please continue to Section H: Spill Response Teams and Housekeeping on page 48.
SECTION H: SPILL RESPONSE TEAMS AND HOUSEKEEPING

H1. Are there special "spill teams" designated at this facility to respond to spills of hazardous materials?

☐ Yes
☐ No ☒ Skip to Section I on Page 50.

H2. Which of the following types of hazardous materials would be cleaned-up by specially-designated spill teams? (Please ✓ all that apply).

☐ Antineoplastic agents
☐ Other hazardous drugs including ribavirin, pentamidine, and tobramycin
☐ High level disinfectants such as glutaraldehyde, ortho-phthalaldehyde, peracetic acid, or hydrogen peroxide
☐ Chemical sterilants such as ethylene oxide or hydrogen peroxide
☐ Volatile anesthetic agents
☐ Other (Please specify): __________________________

H3. Are there written standard procedures for the clean-up of spills of hazardous materials at this facility?

☐ Yes
☐ No

H4. How many workers at this facility are currently assigned to the hazardous materials spill team(s)?

☐ 1
☐ 2-5
☐ 6-10
☐ 11-20
☐ > 20

H5. When do workers at this facility who clean-up spills of hazardous materials receive training on the hazards of the materials they may encounter? Please ✓ all that apply.

☐ Never ☒ Skip to Question H7.
☐ At job orientation
☐ At least annually (i.e., one or more times every 12 months)
☐ Other (Please specify) ______________________________
H6. Which of the following elements are included in the training program for individuals assigned to the spill team? Please mark all that apply.

- Hazard assessment
- Personal Protective Equipment selection
- Emergency communication procedures
- First aid procedures
- Chemical neutralizing techniques
- Proper clean-up procedures
- Packaging for disposal
- Critiquing of incidents
- Other: Please specify: __________________________

H7. Please check the types of personal protective equipment/clothing that are required for workers when cleaning up spills of hazardous materials at this facility. Please answer for the following four hazardous materials and for each of the types of PPE. (Check the boxes in part "a" if the particular material is not cleaned-up by the spill team or not used at this facility, and check the boxes in part "b" if no personal protective equipment is required for employees cleaning-up a particular type of hazardous material.)

<table>
<thead>
<tr>
<th>Personal Protective Equipment (PPE) Type</th>
<th>Hazardous drugs including antineoplastic agents and aerosolized medications</th>
<th>High Level Disinfectants</th>
<th>Chemical sterilants</th>
<th>Volatile anesthetic agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. This material is not used at this facility........................................</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>b. None are required..........................</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>c. Water resistant gown or garment.......</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>d. Water resistant gloves...................</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>e. Eye protection (e.g., face shield, splash goggles, or safety glasses)...</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>f. Elastomeric half-mask or full-facepiece respirator with replaceable cartridges</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>g. Powered air purifying respirator (PAPR).................</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>h. Other respirator (excluding surgical mask).................................</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>i. Other PPE (Please specify): ................</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
</tbody>
</table>

Thank you for completing Section H. Please continue to Section I: Closing on page 50.
SECTION I: CLOSING

11. Please select the positions or titles of the people who have provided information used in completing this questionnaire. Please ✓ all that apply.
   - Director of Nursing
   - Health and Safety Director
   - Human Resource manager
   - Medical Director
   - Oncology Department Manager
   - Operating Room Director
   - Pharmacy Manager
   - Sterile Processing Manager
   - Other (Please specify): ____________________________

12. What is the name, title, and telephone number of the individual who coordinated the completion of this survey?

Name: ____________________________

Title: ____________________________

Telephone Number: ____________________________

Thank you.